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Background: Transforming growth factor-b1 (TGF-b1), a multifunctional cytokine, has been
implicated to be responsible for the increased deposition of extracellular matrix in the
airways, and increased submucosal collagen expression in chronic obstructive pulmonary
disease (COPD). We determined plasma TGF-b1 levels in patients with COPD and explored its
association with common functional polymorphisms of TGF-b1 gene at C-509T and T869C in
the development of COPD in a caseecontrol study.
Methods: Stable COPD patients who were ever smokers, and age and pack-years smoked
matched healthy controls (nZ 205 in each group) were recruited for measurement of plasma
TGF-b1 levels using commercially available ELISA kit, and genotyped at C-509T and T869C func-
tional polymorphisms of TGF-b1 gene using polymerase chain reaction and restriction fragment
length polymorphism (PCReRFLP).
Results: COPD patients had significantly elevated plasma TGF-b1 levels in comparison to
healthy controls irrespective of the genotypes. Allele frequencies and genotype distributions
at both polymorphic sites were not different among COPD patients or controls. TGF-b1 levels
were inversely correlated (Pearson’s correlation analysis) with FEV1 (% predicted) (p < 0.001)
and FVC (% predicted) (p < 0.001).dministration Block, Queen Mary Hospital, Pokfulam Road, Hong Kong SAR, China. Tel.: þ86 852 2855
(J.C.W. Mak).
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1084 J.C.W. Mak et al.Conclusion: The findings of elevated plasma TGF-b1 levels in patients with COPD suggest that
TGF-b1 may play a role in COPD pathogenesis. The C-509T and T869C functional polymorphisms
of TGF-b1 gene do not represent a genetic predisposition to COPD susceptibility in Hong Kong
Chinese patients.
ª 2009 Elsevier Ltd. All rights reserved.Introduction
The prevalence of chronic obstructive pulmonary disease
(COPD) is increasing all over the world, as is the mortality
rate.1 COPD is a slowly progressive and irreversible disorder
characterized by the functional abnormality of airway
obstruction due to chronic bronchitis, emphysema and/or
small airways disease.2 Cigarette smoking is the major risk
factor, accounting for 80e90% of the COPD cases.3 The risk
of developing COPD among continuous smokers has been
estimated to be 25%.4
Transforming growth factor-b1 (TGF-b1) is a multifunc-
tional cytokine with many different effects on cell prolif-
eration and differentiation and on inflammation5 TGF-b1 is
implicated in several aspects of fibrosis, including the
deposition of extracellular matrix proteins such as colla-
gens and fibronectin.6 Animal studies have shown that
TGF-b1 has an inhibitory effect on immunoglobulin
synthesis by lymphocytes and can suppress airway hyper-
responsiveness and inflammation.7 Higher TGF-b1 expres-
sion has been found in airway epithelium of smokers with
COPD than in smokers without COPD, and in lung tissue
from smokers with chronic bronchitis than from nonsmokers
in some studies8,9 but not in another study.10 The data on
the circulating TGF-b1 between COPD patients and healthy
controls have been inconsistent.11,12 The production of
TGF-b1 has been reported to be under genetic control.
13,14
The TGF-b1 gene is located on chromosome 19q13 and has
been cloned and sequenced.15 There are several registered
polymorphisms within TGF-b1 and its promoter that might
be functional.16 Two polymorphisms of the TGF-b1 gene,
C-509T and/or T869C, have been found to be associated
with COPD in Caucasians and Chinese17e19 but not in
Korean20 but correlation between plasma TGF-b1 levels and
the genotypes have not been carried out.
In the present study, we measured plasma TGF-b1 levels
in all patients with COPD and age-/pack years-matched
healthy controls. We also genotyped and evaluated the
association of TGF-b1 gene at C-509T and T869C genetic
variants regulating the expression of TGF-b1 with the
development of COPD in Hong Kong Chinese population.Methods
Subjects
205 consecutive patients with COPD who were ex- or
current smokers were recruited from outpatient respiratory
clinics of 5 different hospitals across Hong Kong if they
satisfied the clinical criteria of COPD according to the
Global Strategy for Obstructive Lung Disease (GOLD)
guidelines.21 Exclusion criteria were history of asthma orother lung diseases. They all had postbronchodilator FEV1
of <80% predicted, FEV1/FVC of <70% and FEV1 broncho-
dilator response of <12% and less than 200 ml with or
without symptoms of cough, phlegm and shortness of
breath on exertion. Each patient was matched for age
(5 years) and pack-years smoked (5 years) with
a healthy control without respiratory symptoms and with
normal lung function (FEV1  80% predicted and FEV1/
FVC  70%) according to their smoking status. The pre-
dicted values were based on reference values obtained
from the local population.22 The healthy controls were
recruited from the general population as described in
a previous communication,22 or from community centers
and churches for the elderly in different parts of Hong
Kong. In addition to lung function testing, these subjects
were interviewed with a questionnaire for information on
smoking habits, respiratory symptoms and other illnesses.
Ever smokers included current smokers and ex-smokers who
were defined as those who had not smoked within the last
12 months prior to the study.
Spirometry was carried out in all patients and controls
using standardized methods according to the American
Thoracic Society criteria.23 In addition, a venous blood
sample of 10 ml was taken from each participant. All
patients and healthy controls were either born in Hong Kong
or migrated from the Province of Guangdong, where Hong
Kong is situated. The Ethics Committee of The University of
Hong Kong has approved the study. Informed consent was
obtained from each participant of the study.
Blood collection and storage
10 ml of whole blood in lithium heparin or in EDTA was
taken from each subject and immediately centrifuged at
1600  g for 10 min at 4 C. Red blood cells, buffy coat and
plasma were separated and stored at 70 C until assayed.
Genotyping
DNA was extracted from buffy coats using commercially
available DNA extraction kit (QIAGEN Inc.; Hilden,
Germany). The genotypes of C-509T (rs1800469) and T869C
(rs1982073) of TGF-b1 gene were determined by polymerase
chain reactionerestriction fragment length polymorphism
(PCReRFLP) as described previously.24 The T869C variant
was amplified using the GC-rich PCR system (Roche; Man-
nheim, Germany). The PCR products were digested with
restriction enzyme DdeI for C-509T and BglI for T869C,
respectively, and electrophoresed on 4% agarose gels.
Samples were genotyped from the digested band sizes. The
genotype of DNA samples was identified blindly and
controls were prepared and set up in association with every
single PCR operation as blank control (without DNA
Table 1 Characteristics of study subjects.
Healthy controls COPD patients
N 205 205
Gender (F/M) 4/201 19/186
Age (yrs) 66.9  9.3 67.2  8.5
Smoking status
Current smokers 100 43
Ex-smoker 105 162
Pack-years smoked 36.7  23.0 37.0  22.9
FEV1 % predicted
a 101.3  13.2 36.9  15.4
FVC % predicteda 101.0  12.1 69.4  20.7
Means  SD are shown.
a Differences between groups by t test.
Plasma TGF-b1 levels in COPD 1085template), positive control, and negative control. For any
samples where amplification or digestion failed, analyses
were repeated at least once.
TGF-b1 measurement
Plasma was available for measurement of TGF-b1 only in
174 patients and 183 healthy ever smokers. The biologically
active TGF-b1 concentration, after release from latent
complexes by acidification, was determined using
commercially available ELISA kit (BD OptEIA Set for
human TGF-b1; San Diego, CA, USA). Plasma samples were
activated and diluted with assay buffer as manufacturer’s
instructions, bringing TGF-b1 values of all the diluted
samples within the linear range of the standard curve
(62.5e4000 pg/ml). Final plasma TGF-b1 concentrations
were obtained by multiplication with the dilution factor. All
samples from patients and controls were measured in
adjacent wells to minimize assay variability. The repro-
ducibility, calculated as the coefficient of variation (CV),
was 7.5%.
Statistical analysis
Demographic data were compared for differences between
groups using Student t test or c2 test whichever was
appropriate. Data for plasma TGF-b1 levels judged to be
skewed by the KolmogoroveSmirnov test were log-trans-
formed and summarized using median (interquartile range).
Differences in plasma levels of TGF-b1 between patients
and controls and between different genotypes were
examined by Student t test.
Differences in genotype and allele frequencies between
patients and controls were tested by using c2 analyses for
a 2  2 table or by using the Fisher exact test. The odds
ratios (OR) and 95% confidence intervals (CI) of COPD risk of
individuals with various genetic polymorphisms were
calculated using logistic regression analysis between COPD
patients and healthy ever smokers. Pairwise linkage
disequilibrium coefficients (D0), and HardyeWeinberg
equilibrium were estimated using SNPAnalyzer program
(Istech Inc., Goyang-si, Korea; http://istech21.com/).
The significance of polymorphisms of various genotypes
in relationship to the severity of COPD was also analyzed
with patients categorized into severity groups by level of
FEV1 % predicted: 50%e79%, 30e49% and <30% accord-
ing to the GOLD guidelines.
Pearson’s correlation coefficients between plasma
TGF-b1 levels (log-transformed) and lung function were
obtained. SPSS for Windows version 16.0 statistical package
(SPSS, Chicago, IL) was used for statistical analyses. A p value
of <0.05 was considered statistically significant.
Power calculation
The statistical power of the study sample sizes of cases and
controls for detecting an association between the putative
risk alleles of TGF-b1 gene polymorphism and COPD was
calculated with the Genetic Power calculator.25 Given the
frequencies observed in previous studies17e20 for the
putative risk alleles and assuming relative risks between 1.7and 2.8, our caseecontrol study has 80% power to detect
significant differences at an a level of 5%.
Results
The characteristics of the study subjects are shown in
Table 1. There were 205 pairs matched for age and packed
years smoked. Among them, 19 COPD patients and 4
healthy controls were females. Compared with healthy
ever smokers, COPD patients showed significantly lower
FEV1 (% predicted) and FVC (% predicted).
We found that plasma levels of TGF-b1 were significantly
elevated in COPD patients compared with healthy controls
of the same genotypes (Table 2). However, we observed no
significant differences in plasma levels of TGF-b1 between
different genotypes among healthy controls or COPD
patients. There was a trend for plasma levels of TGF-b1 to
be higher among current smokers than ex-smokers in COPD
patients or healthy controls (Fig. 1). Pearson’s correlation
analysis showed that plasma TGF-b1 levels were inversely
associated with FEV1 (% predicted) (Fig. 2), and FVC
(% predicted) (p < 0.001; Fig. 3) in our study population.
No differences were found in the distribution of geno-
types and alleles of TGF-b1 gene polymorphisms at C-509T
and T869C in COPD patients and healthy controls (Table 3).
The genotype distribution of both polymorphisms were
consistent with the HardyeWeinberg equilibrium and both
polymorphisms at C-509T and T869C were in tight linkage
disequilibrium (D0 Z 0.9880 and 0.9616 in COPD patients
and healthy controls respectively). There were also no
significant differences in the distribution of genotypes and
alleles of TGF-b1 gene polymorphisms at C-509T and T869C
between healthy controls and COPD patients of varying
severity (Table 4).
Discussion
Since only 25% of continuous smokers develop clinically
significant airflow obstruction,4 it has been suggested that
individual susceptibility may be crucial in the pathogenesis
of COPD. We demonstrated a negative correlation between
circulating levels of TGF-b1 and FEV1 (% predicted), or FVC
(% predicted) in our study population, supporting a possible
role for TGF-b1 in COPD pathogenesis. Several factors may
contribute to TGF-b1 overproduction in patients with COPD
Table 2 Plasma levels (pg/ml) of TGF-b1 in age-/pack
years-matched healthy ever smokers and patients with
COPD according to genotypes.
Healthy controls COPD patients
C-509T
Genotype
CC 3064 (1952e4070)
(36)
6125a (4317e8503)
(33)
CT 3032 (1867e4254)
(90)
7018a (4949e9557)
(88)
TT 2362 (1761e3737)
(68)
6482a (4750e8767)
(65)
T869C
Genotype
TT 3340 (1971e4329)
(39)
6128a (4327e8193)
(34)
TC 2910 (1669e4222)
(92)
7189a (4822e9583)
(86)
CC 2377 (1830e3732)
(63)
6482a (4923e8925)
(65)
Medians (interquartile range) are shown.
a p < 0.001 for comparison between healthy controls and
COPD patients among ever smokers.
Figure 2 Correlation between FEV1 (% predicted) and plasma
TGF-b1 concentration. Pearson’s correlation coefficient (r) is
given.
1086 J.C.W. Mak et al.including genetics. However, we found no significant
differences in the distribution of genotypes and alleles of
TGF-b1 gene polymorphisms at C-509T and T869C between
COPD patients and controls matched for age and pack years
smoked. The lack of association of C-509T and/or T869C
polymorphisms of TGF-b1 gene in COPD patients in our
population was contrary to that reported among Caucasians
in the United States, New Zealand and in other Chinese
populations,17e19 but in agreement with that reported in
a Korean population.20 We also found no association
between TGF-b1 gene polymorphisms at C-509T and T869C,
and severity of airflow obstruction in our COPD patients as
reported in a recent study.240
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Figure 1 Plasma TGF-b1 level in all age-/pack years-matched
healthy controls according to smoking status (n Z 105
ex-smokers and 99 current smokers respectively) and COPD
patients (n Z 149 ex-smokers and 40 current smokers respec-
tively). Means  SEM are shown. ***p < 0.001 for comparison of
ex-smokers or current smokers between COPD patients and
healthy controls respectively.Both C-509T and T869C polymorphisms investigated in
this study have been reported to be associated with the
transcriptional activity of the gene or the serum level of the
gene product. The CC genotype of C-509T polymorphism
was associated with significantly lower circulating level of
TGF-b1 compared with other genotypes in Caucasian
women and Indian populations15,26 while the CC genotype
of the T869C polymorphism was associated with higherFigure 3 Correlation between FVC (% predicted) and plasma
TGF-b1 concentration. Pearson’s correlation coefficient (r) is
given.
Table 3 Genotype distributions and allele frequencies of
C-509T and T869C polymorphisms of TGF-b1 gene in healthy
controls and COPD patients.
Healthy controls,
N (%)
COPD patients,
N (%)
p value
C-509T
Genotype
CC 36 (18.5) 35 (17.3) 0.923
CT 90 (46.1) 97 (48.0)
TT 69 (35.4) 70 (34.7)
Allele
C 162 (41.5) 167 (41.3) 1.000
T 228 (58.5) 237 (58.7)
T869C
Genotype
TT 39 (20.0) 38 (18.9) 0.817
TC 93 (47.7) 92 (45.8)
CC 63 (32.3) 71 (35.3)
Allele
T 171 (43.8) 168 (41.8) 0.566
C 219 (56.2) 234 (58.2)
Plasma TGF-b1 levels in COPD 1087TGF-b1 concentration than other genotypes in a Japanese
study.27 We were unable to find such associations, similar to
one previous report in Caucasian.28
TGF-b1 induces a wide diversity of biological processes
that regulate growth and differentiation of cells, tissue
repair, and extracellular matrix component production.
Using an animal model, one study reported abnormalities in
the activation and signaling of TGF-b1 to be important in
the pathogenesis of emphysema.29 Our data do not permit
us to determine whether TGF-b1 overproduction is the
cause or consequence of COPD. In this study, COPD patientsTable 4 Genotype frequencies of C-509T and T869C polymorp
classified according to severity of airflow obstruction.
Polymorphic sites Healthy controls, N (%) COPD
FEV1 FEV1
80% 50e
C-509T
Genotype
CC 36 (18.5) 7 (1
CT 90 (46.1) 20 (5
TT 69 (35.4) 10 (2
Allele
C 162 (41.5) 34 (4
T 228 (58.5) 40 (5
T869C
Genotype
TT 39 (20.0) 8 (1
TC 93 (47.7) 19 (4
CC 63 (32.3) 10 (3
Allele
T 171 (43.8) 35 (4
C 219 (56.2) 39 (5had higher plasma levels of TGF-b1 compared with healthy
controls irrespective of whether they were current smokers
or ex-smokers, suggesting that this could be the result of
inflammatory process associated with COPD and TGF-b1
might be released by the inflammatory cells. As the disease
progresses and airflow obstruction increases, TGF-b1 is
being produced in larger amounts in activated macrophages
in response to tissue injury and accumulates in the circu-
lation. The findings of higher TGF-b1 expression in airway
epithelium of smokers with COPD than in smokers without
COPD, and in lung tissue from smokers with chronic bron-
chitis than from nonsmokers8,9 are in support of such
a hypothesis although, Kokturk et al.10 were not able to
confirm the increased expression of TGF-b1 in biopsy of the
airway in patients with COPD. On the other hand, elevated
TGF-b1 level from cigarette smoking may stimulate tissue
remodeling responses and may lead to emphysema and/or
fibrosis in the injured lung. Rahman and co-workers30 have
found correlation between increased TGF-b1 expression and
immunoreactivity for 4-hydroxy-2-nonenal, a marker of
oxidative stress in peripheral lung tissue of COPD patients.
TGF-b1 is secreted in a latent form that is inactive but is
potently activated by MMP-9.31 MMP-9-/- mice are not pro-
tected against emphysema induced by cigarette smoke, but
they are protected from small airway fibrosis.32 Further-
more, studies on the differential expression of genes
between normal smokers and COPD patients at GOLD stage
2 revealed marked elevation of TGF-b1.
33
For the majority of multifactorial diseases, such as
COPD, it is unlikely that a single polymorphism in a single
gene could alter expression or function of specific protein
to produce pathologic phenotypes but rather the result of
combined effects of different single nucleotide poly-
morphisms (SNPs) in a gene leading to changes in expres-
sion/function. The G915C polymorphism located within
exon 1 at codon 25 has been found to be associated withhisms of TGF-b1 gene in healthy controls and COPD patients
patients, N (%) p value
FEV1 FEV1
79% 30e49% <30%
8.9) 14 (16.5) 13 (17.6) 0.851
4.1) 43 (50.6) 31 (41.9)
7.0) 28 (32.9) 30 (40.5)
5.9) 71 (41.8) 57 (38.5) 0.765
4.1) 99 (58.2) 91 (61.5)
9.3) 14 (21.1) 15 (20.5) 0.867
0.9) 40 (45.3) 30 (41.1)
9.8) 31 (33.6) 28 (38.4)
7.3) 68 (40.0) 60 (41.1) 0.682
2.7) 102 (60.0) 86 (58.9)
Table 5 Power calculations for a sample size of n Z 205
ever smoking patients with COPD and 205 healthy ever
smokers with a Z 0.05 and b Z 0.80 for a two-sided test.
Prevalence of
polymorphisma
Minimum detectable
relative risk
5% 2.8
10% 2.2
20% 1.9
30% 1.8
40% 1.7
50% 1.7
a Individuals who have either one or two copies of the puta-
tive risk allele.
1088 J.C.W. Mak et al.decreased production of TGF-b1 in vitro (C allele),
increased frequency of lung fibrosis and a more rapid
decline of lung function in patients with cystic fibrosis.34
We have not yet studied this polymorphism because the
variability at this site has not been reported in populations
from Korea, Japan and China.35e37
In this study, we performed not only plasma TGF-b1
measurement but also genotype analysis to determine
whether TGF-b1 gene polymorphisms at C-509T and T869C
were associated with functional activity such as regulation
of its expression. Our cases and controls are well matched
for age and pack-years smoked to avoid the confounding
effect since serum levels of TGF-b1 was found to be
inversely correlated with age and positively correlated with
smoking in healthy Japanese individuals.38 We included
subjects of Chinese ethnic origin from Hong Kong or from
the Province of Guangdong where Hong Kong is situated, to
avoid ethnic differences. The sample size was moderate,
greater than three previous studies,18e20 but less than the
others.17,24 Power calculation showed that our sample size
of 205 in each group should be adequate to detect relative
risks in the range of 1.7e2.8 (Table 5). There are limitations
to our study. The measurement of TGF-b1 levels had been
carried out only in plasma, which might not reflect the local
levels in the lungs. Other biological samples such as BAL,
induced sputum and exhaled breath condensate, might be
more appropriate. Additionally we measured TGF-b1 level
at a single time point, which ignores any variability in this
parameter over time.
In conclusion, we found that polymorphisms of TGF-b1
gene at C-509T and T869C are not related to plasma TGF-b1
levels and are not associated with increased susceptibility
to development of COPD from cigarette smoking in Hong
Kong Chinese population. However, we found elevation of
plasma TGF-b1 levels in patients with COPD which were
negatively correlated with lung function parameters (FEV1
or FVC % predicted), suggesting that TGF-b1 may be
involved in the pathogenesis. Further studies are required
to confirm this finding and to determine its role in the
disease process.
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